Press release content from Business Wire. The AP news staff was not involved in its creation.
AriBio Co., Ltd. Announces Last Patient Last Visit in Phase 2 Clinical Trial of AR1001 in Mild to Moderate Alzheimer’s Patients
January 21, 2021 GMT
SEONGNAM, South Korea (BUSINESS WIRE) Jan 21, 2021
AriBio Co., Ltd., a clinical-stage biopharmaceutical company based in South Korea, announced today, 21 st of January 2021, the completion of last patient last visit in a Phase 2 study of AR1001. AR1001 is a first-in-class, orally dosed investigational drug for mild to moderate Alzheimer’s disease. A total of 210 patients were enrolled, and 171 (81.4%) subjects completed 6-month dosing in the study.